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ABSTRACT
The oxidative behaviour of fluoxetine was studied at a glassy carbon electrode in various buffer systems and at different pH 
using cyclic, differential pulse and square wave voltammetry.  A new square wave voltammetric method suitable for the quality 
control of fluoxetine in commercial formulations has been developed using a borate pH 9 buffer solution as supporting electrolyte.  
Under optimized conditions, a linear response was obtained in the range 10 to 16 μM with a detection limit of 1.0 μM.  Validation 
parameters such as sensitivity, precision and accuracy were evaluated.  The proposed method was successfully applied to the 
determination of fluoxetine in pharmaceutical formulations.  The results were statistically compared with those obtained by the 
reference high-performance liquid chromatographic method.  No significant differences were found between the methods. 
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INTRODUCTION
Depression is a significant and prevalent illness that 
has far-reaching effects on patients’ quality of life, survival, 
and overall health care utilisation and needs(1).
The class of drugs known as selective serotonin 
reuptake inhibitors (SSRIs), which are clinically effective 
for the treatment of depression, makes one of the major 
medicinal discoveries of the past few decades(2).  Their 
therapeutic usefulness is still being expanded to include 
new indications, such as anxiety and compulsive, post 
traumatic stress and pre-menstrual dysphoric disorders(2). 
Among SSRIs, f luoxetine, (±)-N-methyl-3-phenyl-
3-[(α,α,α-trif luoro-p-tolyl)oxy]propyl-amine (Figure 
1), has become one of the most commonly prescribed 
antidepressant drugs worldwide and as such has received 
a great deal of media attention.
Fluoxetine is recommended at an initial daily dose of 
20 mg.  Caution is advised.  A lower or less frequent dose 
should be considered, when fluoxetine is administered to 
patients using multiple concomitant medications or with 
concurrent disease(3).
The demand for fluoxetine analytical assay is growing 
with the increased use of the drug in order to monitor both 
compliance and unexpected toxic concentrations after 
a chronic use of the drug.  Thus, reliable, accurate and 
sensitive analytical procedures are needed to determine 
the drug levels either in quality control or in therapeutic 
drug monitoring.
Several methods for f luoxetine determination have 
been reported in the literature.  Most of these studies 
have determined the concentration of this compound 
employing gas-chromatography and high-performance 
liquid chromatography(4-6).  Official pharmacopoeias, 
such as the Br it ish Pharmacopoeia and the United 
States Pharmacopoeia(7-8), repor t the use of l iquid 
chromatography with UV detection for the determination 
of fluoxetine in formulations, capsules and oral solutions.
Spectrophotometric methods and capillary zone 
elect rophoresis have also been used to determine 
f luoxetine in biological samples and pharmaceutical 
formulations(9-12). 
Electrochemistry has always provided analytical 
techniques characterised by instrumental simplicity, 
moderate cost and portability.  These features make 
electrochemical techniques particularly suitable for the 
determination of trace concentrations of biologically and 
clinically important compounds(13).  Regarding the interest 
and widespread use of electrochemical detectors, such as, 
in liquid chromatographic systems, it is intriguing that 
they had never been used for the analysis and detection *  Author for correspondence. Tel: +351-22-8340500; Fax: +351-22-8321159; E-mail: emg@isep.ipp.pt
Figure 1. Structural formulae of fluoxetine.
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of f luoxetine although the molecule structure possesses 
functional groups susceptible of being oxidable.  In view 
of this, this study investigated the possibility of using 
electrochemical detection to analyse and quantify fluoxetine.
This work aimed to study the voltammetric behaviour 
and to establish the experimental conditions for the 
determination of fluoxetine using a glassy carbon electrode. 
A simple and rapid voltammetric procedure was to be 
developed and applied to the determination of fluoxetine in 
pharmaceutical dosage forms.
EXPERIMENTAL
I. Materials and Method
Voltammet r ic measu rements were per for med 
using an Autolab PGSTAT 10 potentiostat/galvanostat 
(EcoChimie, Netherlands) electrochemical analyser.  A 
glassy carbon working electrode (Metrohm; diameter: 2 
mm), an Ag/AgCl reference electrode (Metrohm; 3M KCl), 
a glassy carbon rod counter electrode (Metrohm) and a 
standard one-compartment three-electrode cell were used 
in all experiments.  The working electrode was polished 
manually with aqueous slurry of alumina powder (BDH) 
on a microcloth pad and rinsed with water before use.  All 
measurements were made at room temperature.
The optimum instrumental parameters to be used 
in the square wave voltammetric (SWV) quantification 
were chosen by studying the variation of the peak current 
(Ip) with the square wave frequency ( f ), pulse amplitude 
(Es) and ionic strength (I).  The system was optimised, 
particularly in respect of maximum peak current and 
reproducibility.
The pH was measured using a Metrohm E-520 pH-
meter and a Metrohm glass electrode.
The HPLC reference method(7-8) was performed using 
a Sykam model A 1210 liquid chromatograph (Sykam, 
Germany), equipped with an UV detector (λ = 203 nm) 
model 3200.  Separation of sample components was 
accomplished at room temperature by gradient elution 
using a Nucleosil 120-5 C18 column (250 × 4.6 mm, 5 μm 
particle size, Macherey-Nagel, Germany).  The mobile-
phase was 20 mM phosphate buffer pH 3.8 - acetonitrile, at 
a flow rate of 1.0 mL per minute.  The acetonitrile content 
of the mobile phase was increased linearly from 25% to 
40% during the first 10 min and then to 44% in 8 min.
II. Chemicals
Fluoxetine hydrochloride was provided by Merck 
Farma (Lisboa, Portugal).  Analytical grade reagents 
purchased from Merck (Darmstadt, Germany) were 
used without additional purification. Deionised water 
(conductivity < 0.1 μS cm-1) was used throughout the 
experiments.  Buffer solutions employed for voltammetric 
determinations were 0.2 M in the pH range 1.2 - 12.2.
HPLC-grade acetonitrile was obtained from Merck. 
Phosphate buffer 20 mM was prepared in water and 
the pH was adjusted to 3.8 with 10% orthophosphoric 
acid.  Prior to use, the solvents were filtered and air was 
removed with helium.
A standard stock solution of fluoxetine (1 mM) was 
prepared in deionised water.  Standard solutions were 
prepared in the voltammetric cell, adding accurate volumes 
of the stock standard solution to the selected borate pH 9 
supporting electrolyte in order to obtain concentrations 
between 10 and 16 μM.  The calibration curve for SWV 
analysis was constructed by plotting the peak current 
against the fluoxetine concentration (10.0, 11.5, 13.0, 14.5 
and 16.0 μM).  The limit of quantification (LOQ) and the 
limit of detection (LOD) were calculated according to 
USP guidelines(8).  A S/N ratio of ten and three was used 
respectively. Method precision was checked at different 
days, within day (n = 5) and between days (n = 5) for three 
different concentrations.  The accuracy of the proposed 
method was determined by comparing the results obtained 
with those from reference methods(7-8).
III. Pharmaceutical Dosage form Assay Procedure
Fluoxetine content was determined in commercial 
formulations available in Portugal; each capsule contains 
20 mg of fluoxetine and the oral solution holds 20 mg per 
5 mL of fluoxetine.
The average mass of ten capsules was determined. The 
capsule contents were emptied as completely as possible. 
An adequate amount of this powder equivalent to 1 mM was 
weighed and dissolved with deionised water.  The solution 
was filtered to remove any remaining insoluble matter. 
Working solutions of the pharmaceutical formulations 
were prepared exactly as the standard solutions.  A suitable 
volume of oral solution was just diluted with water to 
achieve the appropriate concentration.
RESULTS AND DISCUSSION
As no electrochemical data was available concerning 
its oxidative behaviour, the electrochemical oxidation of 
f luoxetine was studied in a broad pH range (1.2 – 12.2) 
using a glassy carbon electrode.  The differential pulse 
voltammetric (DPV) behaviour of f luoxetine yielded 
one anodic wave starting at pH 6 (Figure 2).  As the pH 
increase, a second poorly resolved wave appears at pH 8 
(Figure 2).  The peak potential (Ep) of the oxidation process 
moved to less positive potential by raising the pH (Figure 
3).  The influence of pH on the fluoxetine peak current at 
a glassy carbon electrode was also studied. The Ip versus 
pH plot shows that peak current reaches a maximum value 
at pH 9 (Figure 3).  The experimental results showed that 
shapes of the curves were better defined in borate buffer 
pH 9 than in ammonia or Britton-Robinson buffers.  Hence, 
this electrolyte was used throughout this study.
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The cyclic voltammetric behaviour of f luoxetine at 
pH 9 presented one well-defined wave at Ep = + 0.90 V. 
Cyclic voltammetric measurements showed an irreversible 
nature of the oxidation process, since no reduction wave 
was observed on the cathodic branch.  It was also observed 
that at the second and higher cycles the fluoxetine current 
intensity decreased.  This occurrence could be attributed 
to the adsorption of the oxidation products on the electrode 
surface.  Scan rate studies were carried out to assess 
whether the oxidation process at the glassy carbon electrode 
was under diffusion or adsorption control.  The scan rate 
(ν) varied from 10 to 1000 mV s-1 in 100 μM solution of 
fluoxetine.  From the dependence of peak current on sweep 
rate, it is possible to conclude that the process is diffusion 
controlled between 10 and 250 mV s-1.  A plot of d log Ip 
/ d log ν over this scan range gave a straight line with a 
slope of 0.58, which also indicates a diffusion-controlled 
process(14).  The peak potential was shifted to more positive 
values on increasing the scan rate, which also confirms the 
irreversible nature of the oxidation process.
In order to prevent adsorption of f luoxetine and/or 
its oxidation products on the electrode surface, a study 
on the effect of the addition of different percentages 
of the surfactant, Tween 20, was carried out.  The use 
of low percentages of the surfactant did not eliminated 
completely the adsorption effects observed for high 
concentrations of f luoxetine.  On the contrary, at high 
percentages adsorption of the surfactant itself on the 
electrode surface led to a diminution of the peak current, 
despite the greater reproducibility obtained.  The best 
results were obtained for the addition of 0.5% of Tween 20 
to the solution.
I. Analytical Application of the Proposed Method
A quantitative analytical method was developed 
based on the voltammetric study of fluoxetine.  The best 
ratio of the peak to background currents was obtained 
Figure 2. Differential pulse voltammograms of a 100 μM solutions 
of fluoxetine in (—) pH 6 phosphate buffer, (---) pH 7 phosphate 
buffer, (-∙-∙-) pH 8 phosphate buffer and (∙∙∙∙∙) pH 9 borate buffer. 
Scan rate 5 mV s-1.
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Figure 3. Plots of Ep (filled symbols) and Ip (open symbols) vs. 
pH from differential pulse voltammograms of 100 μM solutions 
of f luoxetine in 0.2 M ionic strength buffer electrolyte. Scan rate 
5 mV s-1.
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Figure 4. Successive square wave voltammograms, in pH 9 borate 
buffer electrolyte, of standard solutions of fluoxetine: A – 0.0, B – 
10.0, C – 11.5, D – 13.0, E – 14.5 and F – 16.0 μM. Frequency 200 
Hz; pulse amplitude 50 mV.
0.6 0.8 1.0
F
E
D
C
B
A
40 nA
Ep / V vs. Ag/AgCl
Journal of Food and Drug Analysis, Vol. 14, No. 3, 2006
245
using square wave voltammetry.  This technique had also 
originated sharper and better defined peaks resulting 
in improved resolution.  Optimisation of the SWV 
parameters regarding peak definition and current was 
accomplished using f = 200 Hz, Es = 50 mV and I = 0.2 M 
(see Experimental section).
Squ a re  wave vol t a m mog ra ms recorded w it h 
increasing amounts of f luoxetine showed that the peak 
current increased linearly with increasing concentration 
(Figure 4).  A linear relation between peak current and 
fluoxetine concentration was observed in the range 10 to 
16 μM.  The characteristics of the calibration plots are 
summarized in Table 1.  The limit of detection (LOD) and 
the limit of quantification (LOQ), calculated according to 
USP guidelines [8], were 1.0 and 7.1 μM, respectively. 
The precision of the method was evaluated at three 
levels of concentration (10, 13 and 16 μM) (results shown 
in Table 1).  Specificity of the optimized procedure for 
the assay of f luoxetine was examined through recovery 
trials, in the presence of excipients (e.g. starch, lactose, 
sucrose) at concentrations that can be found in the 
formulations.  The results indicated the absence of 
significant interference from any of the excipients found 
in the pharmaceutical formulations tested.  On the basis 
of these results, the proposed method was applied to the 
determination of f luoxetine in commercial capsules and 
oral solutions.  To evaluate the accuracy of the proposed 
technique, the results were compared with those obtained 
by the reference method(8) (Table 2).
The F- and Student t-test were carried out on the data 
and statistically examined the validity of the obtained 
results (Table 2).  At the 95% confidence level, the values 
of t- and F-tests were less than the theoretical values 
showing that there are no significant differences between 
the proposed and reference methods.
CONCLUSIONS
This s t udy has shown that  f luoxet ine can be 
determined by using the square wave voltammetric 
technique on the basis of its oxidation process at a glassy 
carbon electrode.  The method has been successfully 
applied to the di rect determinat ion of f luoxet ine, 
without complex pre-treatment of the samples other than 
dissolution or dilution, in pharmaceutical formulations 
with adequate reproducibility and sensitivity.
The reported technique constitutes an alternative 
method that can be implemented for routine analysis of 
fluoxetine in pharmaceutical formulations.  Moreover, the 
results obtained outlook the possibility of development 
of a successful HPLC strategy based on electrochemical 
detection that is ideal for therapeutic drug monitoring 
purposes and to study the metabolism of the drug, which 
could enable the simultaneous determination of fluoxetine 
and its metabolites in biological matrixes.
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Table 2. Application of the square wave voltammetric method 
(SW V) to the deter minat ion of f luoxet ine in commercial 
pharmaceutical preparations.
Formulation SWVa Reference method (HPLC)a
Fluoxetine Irex®
t b
F c
19.6 ± 0.4
1.4
1.6
20.2 ± 0.5
Fluoxetine Merck®
t b
F c
20.2 ± 0.9
0.7
1.0
19.8 ± 0.9
Psipax®
t b
F c
19.9 ± 0.9
0.4
2.2
19.7 ± 0.6
Nodepe ®
t b
F c
20.1 ± 0.9
1.2
1.0
19.4 ± 0.9
Prozac ®
t b
F c
20.5 ± 0.8
0.3
1.3
20.7 ± 0.9
a  Mean and standard deviation of five determinations for different 
samples (mg/tablet or mg/5 mL). 
b  Tabulated t-value for P = 0.05 and eight degrees of freedom is 2.31.
c  Tabulated F-value for P = 0.05 and f1 = f2 = 4 is 6.39.
Table 1. Linearity range, quantification and detection limits and 
intra- and inter-day repeatability for determination of f luoxetine 
using the square wave voltammetric method (SWV).
SWV
Linearity range (μM) 10 - 16
Calibration graph (n = 5)
Intercept (μA)
Slope (mA μM-1)
Correlation coefficient
Standard error of intercept
Standard error of slope
0.023
2.84
0.995
0.03
0.06
Intra-day precision (n = 5)a
               10 μM
               13 μM
               16 μM
2.3
1.6
1.8
Inter-day precision (n = 5)a
               10 μM
               13 μM
               16 μM
3.0
2.1
1.8
LOD (μM) 1.0
LOQ (μM) 7.1
a Precision as coefficient of variation (CV, %) = standard deviation 
divided by mean measured concentration × 100.
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